Elena Lukina Selected Research

eliglustat

1/2023	Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
1/2021	Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials.
1/2021	Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
1/2019	Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
1/2019	Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
1/2018	Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
1/2018	Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
11/2017	Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
1/2017	Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
1/2017	Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elena Lukina Research Topics

Disease

21	Gaucher Disease (Gaucher's Disease) 06/2023 - 03/2010
2	Splenomegaly 01/2019 - 02/2015
2	Anemia 01/2019 - 11/2010
2	Scoliosis 03/2016 - 01/2015
1	Fabry Disease (Fabry's Disease) 01/2023
1	Pain (Aches) 01/2023
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2023
1	Hemolysis 01/2023
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Metabolic Bone Diseases (Osteopenia) 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2020
1	Thrombocytopenia (Thrombopenia) 01/2019
1	Fatigue 03/2017
1	Seroma 03/2016
1	Psychotic Disorders (Schizoaffective Disorder) 06/2015
1	Myocardial Infarction 06/2015
1	Rare Diseases (Rare Disease) 01/2011

Drug/Important Bio-Agent (IBA)

16	eliglustatIBA 01/2023 - 08/2010
5	Hemoglobins (Hemoglobin)IBA 01/2021 - 11/2010
3	ceramide glucosyltransferaseIBA 01/2023 - 08/2010
3	Glucosylceramides (Glucocerebrosides)IBA 01/2021 - 01/2017
3	EnzymesIBA 11/2017 - 01/2011
3	imiglucerase FDA Link 01/2017 - 03/2010
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2017
2	AcidsIBA 01/2021 - 01/2017
2	sphingosyl beta-glucosideIBA 01/2021 - 11/2017
2	GlucosidasesIBA 01/2021 - 01/2017
2	LipidsIBA 01/2021 - 11/2017
2	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 11/2017 - 01/2017
2	IonsIBA 03/2017 - 03/2016
2	nitinolIBA 03/2017 - 01/2015
1	Complement Inactivating AgentsIBA 01/2023
1	venglustatIBA 01/2023
1	GlycosphingolipidsIBA 01/2023
1	Complement System Proteins (Complement)IBA 01/2023
1	globotriaosylceramide (globotriosylceramide)IBA 01/2023
1	Estrogens (Estrogen)FDA Link 01/2022
1	Selective Estrogen Receptor Modulators (SERM)IBA 01/2022
1	Tamoxifen FDA LinkGeneric 01/2022
1	Estrogen ReceptorsIBA 01/2022
1	chitotriosidaseIBA 01/2021
1	Inflammation MediatorsIBA 01/2020
1	SphingolipidsIBA 01/2020
1	Glucosylceramidase (Glucocerebrosidase)IBA 11/2017
1	miglustat (Zavesca)FDA Link 01/2017
1	TitaniumIBA 03/2016
1	MetalsIBA 03/2016
1	AlloysIBA 01/2015
1	ChromiumIBA 01/2015
1	CobaltIBA 01/2015

Therapy/Procedure

14	Therapeutics 06/2023 - 08/2010
6	Enzyme Replacement Therapy 06/2023 - 11/2010
2	Enzyme Therapy 01/2017 - 01/2017
1	Pedicle Screws 03/2017
1	Complementary Therapies (Alternative Medicine) 01/2017